AIDS Weekly Plus
click here to return to AIDS Weekly Plus main menu

Conference Coverage (Vancouver): How Do High-Risk Uninfected Women Resist HIV?

AIDSWEEKLY Plus, 12 Aug 1996
Daniel J. DeNoon, Senior Editor


How do they do it?

Exhaustive immunological studies of Zambian women who remain uninfected despite repeated sexual exposure to HIV revealed only one difference from matched, unexposed women.

"The high risk seronegative women had significantly lower proliferative responses to an alloreactive stimulator cell line," said John F. Krowka of the University of California, San Francisco.

Krowka announced the study findings - and offered several possible explanations for them - at the XI International Conference on AIDS, held July 7-12, 1996 in Vancouver, British Columbia, Canada.

Krowka and colleagues obtained blood samples from 18 HIV negative women married to HIV infected men (the high-risk group) and compared them to blood samples from HIV negative women married to HIV negative men (the low-risk group).

The two groups of women were matched for age, number of children, pregnancy, and duration of marriage.

The blood samples were assayed for peripheral blood lymphocytes (PBL) proliferative responses to Candida, alloantigens, or phytohemagglutinin (PHA); CD4(+) and CD8(+) T-lymphocyte levels; interleukin 2 (IL-2) production by PBL in response to HIV envelope peptides; plasma levels of the C-C cytokines RANTES, MIP1(alpha), and MIP1(beta); and CD8(+) suppressor-phenotype T lymphocytes.

"Of all the parameters tested only the proliferative responses of PBL to one particular allogeneic stimulator cell line (IBC21) were significantly different between high-risk and low-risk women," Krowka et al. wrote in their presentation abstract. "In three independent experiments, the responses to ... IBC21 were significantly lower in PBL from high-risk women."

The researchers offered several interpretations of their data:

Krowka et al. are currently investigating these hypotheses.

Interestingly, no protective effects were seen for high levels of C-C cytokines. These cell-produced antiviral substances were recently reported to have anti-HIV activity, but their role in the pathogenesis of HIV disease has been hotly debated.

"Our data is not showing a protective effect for these cytokines," Krowka said.

960812
AW960807


AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, iMetrikus, Inc., the National Library of Medicine, and donations from users like you. This article first appeard in 1996. This material is designed to support, not replace, the relationship that exists between you and your doctor.

Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633-4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX: (205) 995-1588 http://www.newsrx.net

Copyright © 1996 - Charles Henderson, Publisher. All rights Reserved. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA.


AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
©1996. AEGiS.